96 related articles for article (PubMed ID: 20023051)
1. Investigation of the involvement of P-glycoprotein and multidrug resistance-associated protein 2 in the efflux of ximelagatran and its metabolites by using short hairpin RNA knockdown in Caco-2 cells.
Darnell M; Karlsson JE; Owen A; Hidalgo IJ; Li J; Zhang W; Andersson TB
Drug Metab Dispos; 2010 Mar; 38(3):491-7. PubMed ID: 20023051
[TBL] [Abstract][Full Text] [Related]
2. Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion.
Eriksson UG; Dorani H; Karlsson J; Fritsch H; Hoffmann KJ; Olsson L; Sarich TC; Wall U; Schützer KM
Drug Metab Dispos; 2006 May; 34(5):775-82. PubMed ID: 16455803
[TBL] [Abstract][Full Text] [Related]
3. Intestinal and hepatobiliary transport of ximelagatran and its metabolites in pigs.
Sjödin E; Fritsch H; Eriksson UG; Logren U; Nordgren A; Forsell P; Knutson L; Lennernäs H
Drug Metab Dispos; 2008 Aug; 36(8):1519-28. PubMed ID: 18458048
[TBL] [Abstract][Full Text] [Related]
4. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.
Bredberg E; Andersson TB; Frison L; Thuresson A; Johansson S; Eriksson-Lepkowska M; Larsson M; Eriksson UG
Clin Pharmacokinet; 2003; 42(8):765-77. PubMed ID: 12846597
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers.
Dorani H; Schützer KM; Sarich TC; Wall U; Logren U; Ohlsson L; Eriksson UG
Eur J Clin Pharmacol; 2007 Jun; 63(6):571-81. PubMed ID: 17387462
[TBL] [Abstract][Full Text] [Related]
6. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
[TBL] [Abstract][Full Text] [Related]
7. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug.
Clement B; Lopian K
Drug Metab Dispos; 2003 May; 31(5):645-51. PubMed ID: 12695354
[TBL] [Abstract][Full Text] [Related]
8. Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters.
Ming X; Knight BM; Thakker DR
Mol Pharm; 2011 Oct; 8(5):1677-86. PubMed ID: 21780830
[TBL] [Abstract][Full Text] [Related]
9. Biliary excretion of ximelagatran and its metabolites and the influence of erythromycin following intraintestinal administration to healthy volunteers.
Matsson EM; Eriksson UG; Knutson L; Hoffmann KJ; Logren U; Fridblom P; Petri N; Lennernäs H
J Clin Pharmacol; 2011 May; 51(5):770-83. PubMed ID: 20663994
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in atrial fibrillation patients receiving long-term anticoagulation therapy.
Bååthe S; Hamrén B; Karlsson MO; Wollbratt M; Grind M; Eriksson UG
Clin Pharmacokinet; 2006; 45(8):803-19. PubMed ID: 16884319
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.
Eriksson UG; Bredberg U; Gislén K; Johansson LC; Frison L; Ahnoff M; Gustafsson D
Eur J Clin Pharmacol; 2003 May; 59(1):35-43. PubMed ID: 12743672
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men.
Wernevik LC; Nyström P; Johnsson G; Nakanishi T; Eriksson UG
Clin Pharmacokinet; 2006; 45(1):77-84. PubMed ID: 16430312
[TBL] [Abstract][Full Text] [Related]
13. Comparable pharmacokinetics and pharmacodynamics of melagatran in Japanese and caucasian volunteers after oral administration of the direct thrombin inhibitor ximelagatran.
Wernevik LC; Nyström P; Andersson M; Johnsson G; Bylock A; Nakanishi T; Eriksson UG
Clin Pharmacokinet; 2006; 45(1):85-94. PubMed ID: 16430313
[TBL] [Abstract][Full Text] [Related]
14. Low potential for interactions between melagatran/ximelagatran and other drugs, food, or alcohol.
Wolzt M; Sarich TS; Eriksson UG
Semin Vasc Med; 2005 Aug; 5(3):254-8. PubMed ID: 16123912
[TBL] [Abstract][Full Text] [Related]
15. A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor.
Teng R; Sarich TC; Eriksson UG; Hamer JE; Gillette S; Schützer KM; Carlson GF; Kowey PR
J Clin Pharmacol; 2004 Sep; 44(9):1063-71. PubMed ID: 15317834
[TBL] [Abstract][Full Text] [Related]
16. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux.
Honda Y; Ushigome F; Koyabu N; Morimoto S; Shoyama Y; Uchiumi T; Kuwano M; Ohtani H; Sawada Y
Br J Pharmacol; 2004 Dec; 143(7):856-64. PubMed ID: 15504753
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of ximelagatran.
Wolzt M; Sarich TS; Eriksson UG
Semin Vasc Med; 2005 Aug; 5(3):245-53. PubMed ID: 16123911
[TBL] [Abstract][Full Text] [Related]
18. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Johansson LC; Frison L; Logren U; Fager G; Gustafsson D; Eriksson UG
Clin Pharmacokinet; 2003; 42(4):381-92. PubMed ID: 12648028
[TBL] [Abstract][Full Text] [Related]
19. The oral direct thrombin inhibitor, ximelagatran, an alternative for anticoagulant treatment during the puerperium and lactation.
Hellgren M; Johansson S; Eriksson UG; Wåhlander K
BJOG; 2005 May; 112(5):579-83. PubMed ID: 15842280
[TBL] [Abstract][Full Text] [Related]
20. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans.
Oswald S; Haenisch S; Fricke C; Sudhop T; Remmler C; Giessmann T; Jedlitschky G; Adam U; Dazert E; Warzok R; Wacke W; Cascorbi I; Kroemer HK; Weitschies W; von Bergmann K; Siegmund W
Clin Pharmacol Ther; 2006 Mar; 79(3):206-17. PubMed ID: 16513445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]